Publications + Posters

TNG961: a selective, oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancers

Hit finding and assay enablement for VRK1, a paralog synthetic lethal kinase target in VRK2-deficient cancers

Genome-wide CRISPRi screen identifies RPS27 as a novel synthetic lethal target for TP53 mutant cancers

VRK1 inhibition leverages paralog synthetic lethality to selectively target VRK2-deficient cancer cells

Mass Spectrometry-Based Kinetic and Site-Specific Profiling of Covalent Inhibitors Targeting VRK1